Modality
siRNA
MOA
CFTRmod
Target
CD20
Pathway
Amyloid
HCCCTCL
Development Pipeline
Preclinical
May 2018
→ Aug 2025
PreclinicalCurrent
NCT08530517
681 pts·CTCL
2018-05→2025-08·Recruiting
681 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-08-237mo agoInterim· CTCL
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
Preclinical
Recruit…
Catalysts
Interim
2025-08-23 · 7mo ago
CTCL
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08530517 | Preclinical | CTCL | Recruiting | 681 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 | |
| CRS-6525 | CRISPR Therapeutics | Phase 2 | CD20 |